Essential Vaccine Policy Updates: ACIP, CDC’s COVID-19 Guidance, and What’s Next

JESSE L. GOODMAN, M.D., M.P.H. is Professor of Medicine at Georgetown University and Director of the Center on Medical Product Access, Safety and Stewardship, focusing on science and policy to address public health needs. He is Attending Physician in Infectious Diseases at Georgetown University, Washington DC Veterans Administration and Walter Reed Medical Centers. Until 2014, he was the Chief Scientist of the FDA, also serving as Deputy Commissioner for Science and Public Health and in the government’s senior leadership for the 2009 influenza pandemic and other major public health responses as well as the 2010 White House Medical Countermeasure Review. Prior to that, he directed the Center for Biologics Evaluation and Research (CBER) and before that, as Senior Advisor to the FDA Commissioner, developed and co-chaired the U.S. Task Force to Combat Antimicrobial Resistance (AMR), producing the first National AMR Action Plan. Previously he was Professor of Medicine and Chief of Infectious Diseases at the University of Minnesota, where his laboratory isolated A. phagocytophilum, the causative agent of the tickborne disease human granulocytic anaplasmosis and where he led numerous clinical trials, including development of fluconazole for antifungal prophylaxis in marrow transplantation and leukemia. He has served on various CDC (Board of Scientific Counselors), NIH, DOD, CEPI, National Academy of Medicine (NAM) and WHO Committees, including the WHO Senior Advisory Group of Experts (SAGE) for Immunization and Ebola Vaccine Working Group and, recently, the NAM Consensus Committee on Lyme Infection Associated Chronic Illness. He chaired the multi-institution COVID Vaccine Analysis Team (COVAT), now E-VAT (Expert Vaccine Analysis Team), providing information and analysis on emerging vaccine issues. He has served on the boards of the US Pharmacopeia including as President from 2015-20, GSK (through May, 2025, including chairing its Science Committee), Intellia Therapeutics (chairing its Science and Technology committee) and BiomX. He has been elected to the National Academy of Medicine of the National Academy of Sciences.